August 2, 2021

Eisai’s Anti-Epileptic Drug Fycompa Approved In China As Monotherapy For Partial-Onset Seizures And Pediatric Indication For Partial-Onset Seizures

TOKYO, Aug 2, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that its in-house discovered and developed anti-epileptic drug (AED) Fycompa…

March 26, 2021

Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021

TOKYO, Mar 26, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. has announced that drug discovery research conducted on perampanel (brand name: FYCOMPA,…

October 16, 2020

Eisai: Supplementary New Drug Applications for Anti-Epileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures

TOKYO, Oct 16, 2020 – (JCN Newswire) – Eisai Co., Ltd. announced today that the supplementary new drug applications for its in-house discovered and developed…